Leishmaniasis is a vector-borne neglected tropical disease endemic in over 100 countries
around the world. Available control measures are not always successful, therapeutic options …

Leishmaniasis is a protozoan parasitic disease endemic to the tropical and subtropical
regions of the world, with three major clinical forms, self‐healing cutaneous leishmaniasis …

Background The JAK-STAT signaling pathway is a central cascade of signal transduction for
the myriad of cytokines in which dysregulation has been implicated in progression of …

Cutaneous leishmaniasis (CL) caused by infection with the parasite Leishmania exhibits a
large spectrum of clinical manifestations ranging from single healing to severe chronic …

Understanding the immune response to Leishmania infection and identifying biomarkers
that correlate with protection are crucial for developing effective vaccines. One intriguing …

Leishmania tropica causes different forms of leishmaniasis in many parts of the world.
Animal models can help to clarify the issues of pathology and immune response in L. tropica …

Patients who recover from leishmaniasis usually show development of strong immunity and
induction of interferon-γ (IFN-γ) and delayed type hypersensitivity. In a randomized trial, we …

Introduction Emerging infectious diseases such as SARS-CoV-2 can cause pandemics and
create a critical risk for humans. In a previous pilot study, we reported that the immunological …

The available evidence suggests that protective immunity to Leishmania is achieved by
priming the CD4+ Th1 response. Therefore, we utilised a reverse genetics strategy to …

With limited options to treat cutaneous leishmaniasis, constant monitoring of the rate of
resistance to pentavalent antimony-based drugs is needed. This study identified the …